India Oncology NGS Market to Grow with a CAGR of 7.89% through 2030

Diverse applications of NGS in oncology is expected to drive the India Oncology NGS Market growth in the forecast period, 2026-2030.

According to TechSci Research report, “India Oncology NGS Market – By Region, Competition, Forecast & Opportunities, 2030F”, the India Oncology NGS Market stood at USD 22.01 Million in 2024 and is anticipated to grow with a CAGR of 7.89% in the forecast period through 2030. 

Increasing awareness and education have emerged as key drivers in boosting the India Oncology NGS (Next-Generation Sequencing) Market. The growing recognition of the potential benefits of NGS technology in oncology, both among healthcare professionals and the general public, has had a profound impact on the adoption and expansion of NGS in the Indian healthcare system.

Healthcare professionals, including oncologists, pathologists, and genetic counselors, are increasingly becoming more knowledgeable about NGS technology and its applications in cancer care. This enhanced understanding allows them to appreciate the value of genomic profiling in guiding personalized treatment decisions. As a result, they are more likely to recommend and utilize NGS-based diagnostic tests for their cancer patients, thus driving the market's growth. Medical curriculum in India is adapting to include genomics and NGS training, ensuring that the next generation of healthcare providers is well-prepared to integrate NGS into oncology practice.

The general public's awareness of NGS and its role in oncology is also on the rise. Media coverage, health awareness campaigns, and patient advocacy groups have played a crucial role in educating the public about the potential of NGS technology in cancer diagnosis and treatment. Patients and their families are increasingly informed about the benefits of genomic profiling, precision medicine, and the potential for tailored cancer therapies. This heightened awareness has led to increased patient demand for NGS-based diagnostic services.

Educational initiatives from healthcare institutions, research organizations, and pharmaceutical companies have helped bridge the knowledge gap. Seminars, workshops, and informational resources have been instrumental in disseminating information about the advantages of NGS in oncology. These efforts have not only expanded the pool of informed patients but have also empowered healthcare providers to make more informed decisions regarding the adoption of NGS technology in their practices.

Moreover, advocacy groups and patient success stories have been instrumental in driving awareness and acceptance of NGS in the Indian oncology community. Patients who have benefited from NGS-based personalized treatments have become strong advocates for the technology, sharing their experiences and outcomes. These real-world examples of NGS's potential have a profound impact on influencing both healthcare providers and patients to embrace this cutting-edge approach to cancer care.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on " India Oncology NGS Market”

The India Oncology NGS Market is segmented into Technology, Application, Regional Distribution and Company.

Based on the Application, the Companion Diagnostics segment emerged as the dominated segment in the market for India Oncology NGS Market in 2024. Companion Diagnostics contribute to cost savings in healthcare by avoiding the use of ineffective treatments. Ineffective treatments not only incur high costs but also expose patients to unnecessary side effects. By matching the right treatment to the right patient, Companion Diagnostics can reduce the overall healthcare expenditure and the financial burden on patients. The increased emphasis on precision medicine has transformed the landscape of clinical trials in oncology. Many trials now incorporate Companion Diagnostics to identify patient subpopulations that are more likely to benefit from investigational treatments. This trend has resulted in a growing demand for Companion Diagnostic testing in the pre-trial screening of eligible patients. 

Major companies operating in India Oncology NGS Market are:

• Illumina, Inc
• Genotypic Technology Pvt Ltd
• Tecan Trading AG
• Xcelris Genomics
• Eurofins Scientific Inc.
• Sayre Therapeutics
• Redcliffe Lifesciences
• Partek Inc.
• Bio-Rad Laboratories, Inc.
• Myriad Genetics

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The India Oncology NGS Market is poised for robust growth in the coming years, driven by several compelling factors. The market is expected to expand as advancements in NGS technology continue to make it more accessible and affordable. The rising incidence of cancer, the adoption of precision medicine, government initiatives to improve healthcare infrastructure, private sector participation, and increasing awareness about the benefits of NGS in oncology are all contributing to this positive trajectory. Also, the versatile applications of NGS, particularly in the areas of mutation profiling, liquid biopsy, and companion diagnostics, are expected to bolster the market's expansion.” said Mr. Karan Chechi, Research Director, TechSci Research, a research-based management consulting firm.

“India Oncology NGS Market By Technology (Whole Genome Sequencing, Whole Exome Sequencing, Targeted & Gene Panel Sequencing), By Application (Diagnostics and Screening, Companion Diagnostics, Other Diagnostics), By Region, Competition, Forecast & Opportunities, 2020-2030F”, has evaluated the future growth potential of India Oncology NGS Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in India Oncology NGS Market.

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]               

Website: www.techsciresearch.com